

Hendra Gunosewoyo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9046874/publications.pdf>

Version: 2024-02-01

44
papers

1,180
citations

394286

19
h-index

377752

34
g-index

44
all docs

44
docs citations

44
times ranked

1900
citing authors

#	ARTICLE	IF	CITATIONS
1	Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis. <i>Bioorganic Chemistry</i> , 2021, 106, 104486.	2.0	12
2	Synthesis and Pharmacological Evaluation of β_2 Receptor Ligands Based on a 3-alkoxyisoxazole Scaffold: Potential Antitumor Effects against Osteosarcoma. <i>ChemMedChem</i> , 2021, 16, 524-536.	1.6	4
3	Imaging Cannabinoid Receptors: A Brief Collection of Covalent and Fluorescent Probes for CB. <i>Australian Journal of Chemistry</i> , 2021, 74, 416-432.	0.5	7
4	Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1910-1925.	1.7	1
5	Design, synthesis and evaluation of novel indole-2-carboxamides for growth inhibition of <i>Mycobacterium tuberculosis</i> and paediatric brain tumour cells. <i>RSC Advances</i> , 2021, 11, 15497-15511.	1.7	11
6	Sigma-1 Receptor Agonist TS-157 Improves Motor Functional Recovery by Promoting Neurite Outgrowth and pERK in Rats with Focal Cerebral Ischemia. <i>Molecules</i> , 2021, 26, 1212.	1.7	4
7	Design and synthesis of mycobacterial pks13 inhibitors: Conformationally rigid tetracyclic molecules. <i>European Journal of Medicinal Chemistry</i> , 2021, 213, 113202.	2.6	15
8	Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives. <i>Chemical Biology and Drug Design</i> , 2021, 97, 1137-1150.	1.5	9
9	Therapeutic Potential of Coumestan Pks13 Inhibitors for Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	12
10	Synthesis and evaluation of tetrahydroisoquinoline derivatives against <i>Trypanosoma brucei</i> rhodesiense. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113861.	2.6	2
11	Design, synthesis, and biological evaluation of novel arylcarboxamide derivatives as anti-tubercular agents. <i>RSC Advances</i> , 2020, 10, 7523-7540.	1.7	24
12	Synthesis and evaluation of various heteroaromatic benzamides as analogues of α -ylidene-benzamide cannabinoid type 2 receptor agonists. <i>Tetrahedron Letters</i> , 2019, 60, 151019.	0.7	7
13	Revisiting the β -Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	4
14	Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2112.	1.8	33
15	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against <i>Mycobacterium tuberculosis</i> . Part II. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3575-3589.	2.9	26
16	Therapeutic Inducers of Apoptosis in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1786.	1.7	44
17	Introducing nitrogen atoms to amidoalkylindoles: potent and selective cannabinoid type 2 receptor agonists with improved aqueous solubility. <i>MedChemComm</i> , 2019, 10, 2131-2139.	3.5	9
18	Kinase Targets for Mycolic Acid Biosynthesis in <i>Mycobacterium tuberculosis</i> . <i>Current Molecular Pharmacology</i> , 2019, 12, 27-49.	0.7	15

#	ARTICLE	IF	CITATIONS
19	Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against <i>Mycobacterium tuberculosis</i> . <i>Journal of Medicinal Chemistry</i> , 2018, 61, 791-803.	2.9	56
20	Novel spirocyclic tranlycypromine derivatives as lysine-specific demethylase 1 (LSD1) inhibitors. <i>RSC Advances</i> , 2018, 8, 1666-1676.	1.7	9
21	Efflux transporters and tight junction expression changes in human gastrointestinal cell lines cultured in defined medium vs serum supplemented medium. <i>Life Sciences</i> , 2018, 207, 138-144.	2.0	2
22	Kinase targets in CNS drug discovery. <i>Future Medicinal Chemistry</i> , 2017, 9, 303-314.	1.1	24
23	Tying up tranlycypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 141, 101-112.	2.6	27
24	Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7067-7083.	2.9	29
25	Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models. <i>Translational Oncology</i> , 2017, 10, 669-678.	1.7	32
26	Development of Antidepressant Drugs Through Targeting $\alpha 4\beta 2$ -Nicotinic Acetylcholine Receptors. <i>Neuromethods</i> , 2016, , 207-225.	0.2	0
27	Synthesis and biological evaluation of novel hybrids of highly potent and selective $\alpha 4\beta 2$ -Nicotinic acetylcholine receptor (nAChR) partial agonists. <i>European Journal of Medicinal Chemistry</i> , 2016, 124, 689-697.	2.6	14
28	Development of Novel Alkoxyisoxazoles as Sigma-1 Receptor Antagonists with Antinociceptive Efficacy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6329-6343.	2.9	20
29	Stereoselective synthesis towards unnatural proline based amino acids. <i>Arkivoc</i> , 2016, 2016, 134-144.	0.3	5
30	Optimization of 2-Phenylcyclopropylmethylamines as Selective Serotonin 2C Receptor Agonists and Their Evaluation as Potential Antipsychotic Agents. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1992-2002.	2.9	31
31	Targeting the Number Two Infectious Disease Killer—Tuberculosis. <i>Medicinal Chemistry Reviews</i> , 2015, , 283-296.	0.1	1
32	The First CNS-Active Carborane: A Novel P2X ₇ Receptor Antagonist with Antidepressant Activity. <i>ACS Chemical Neuroscience</i> , 2014, 5, 335-339.	1.7	118
33	Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 285-296.	1.9	56
34	Indoleamides are active against drug-resistant <i>Mycobacterium tuberculosis</i> . <i>Nature Communications</i> , 2013, 4, 2907.	5.8	130
35	Structural analogs of huperzine A improve survival in guinea pigs exposed to soman. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 1544-1547.	1.0	9
36	Preliminary Structure-Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant <i>Mycobacterium tuberculosis</i> Strains. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4093-4103.	2.9	118

#	ARTICLE	IF	CITATIONS
37	Characterization of Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as Stimulators of Steroidogenesis. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 5115-5129.	2.9	36
38	From α -4 β 2 Nicotinic Ligands to the Discovery of α 1 Receptor Ligands: Pharmacophore Analysis and Rational Design. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 1054-1058.	1.3	11
39	Identification of a Glycogen Synthase Kinase β 2 Inhibitor that Attenuates Hyperactivity in CLOCK Mutant Mice. <i>ChemMedChem</i> , 2011, 6, 1593-1602.	1.6	36
40	Structure-Guided Design of a Highly Selective Glycogen Synthase Kinase β 2 Inhibitor: a Superior Neuroprotective Pyrazolone Showing Antimania Effects. <i>ChemMedChem</i> , 2011, 6, 1587-1592.	1.6	14
41	P2X purinergic receptor ligands: recently patented compounds. <i>Expert Opinion on Therapeutic Patents</i> , 2010, 20, 625-646.	2.4	77
42	Purinergic P2X7 receptor antagonists: Chemistry and fundamentals of biological screening. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 4861-4865.	1.4	10
43	Cubyl amides: Novel P2X7 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3720-3723.	1.0	34
44	Molecular Probes for P2X7 Receptor Studies. <i>Current Medicinal Chemistry</i> , 2007, 14, 1505-1523.	1.2	42